DDR1 and fibrosarcoma: Although the study by Wasinski et al., was performed in one fibrosarcoma cell line model and needs to be further investigated in additional patient-derived models, it is possible that TKIs such as imatinib, nilotinib and dasatinib may be considered for repurposing as DDR inhibitors for preclinical and clinical studies in the treatment of fibrosarcoma.